The role of immunologic and viral markers in predicting clinical outcome in HIV infection. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The role of immunologic and viral markers in predicting clinical outcome in HIV infection.

AIDS. 1996 Dec;10 Suppl 5:S21-5. Unique Identifier : AIDSLINE MED/97182352
Graham NM; Johns Hopkins University, Baltimore, Maryland, USA.

Abstract: OBJECTIVE: In an ideal world, one clinical marker would explain all the variance in a disease system. In reality, however, this is rarely the case and HIV disease is no exception. This review considers several specific markers that have demonstrated some use in clinical trials and/or epidemiologic studies of antiretroviral therapy. DISCUSSION: CD4 lymphocyte count, HIV viral load and perhaps immune activation markers can be used to measure the activity of antiretroviral therapy. Some recent studies are presented and the results discussed. CONCLUSION: Sustained improvements in several markers (particularly HIV viral load and CD4 cell count) in combination appear to be the most predictive of clinical benefit. No current viral or immunologic markers adequately reflect toxicities attributable to antiretroviral therapy. Lamivudine/zidovudine combination therapy leads to sustained changes in several markers, and appears to be well tolerated. This may translate into significant clinical benefit but the duration of such benefit remains unknown.
Keywords: *Biological Markers *HIV Infections/PHYSIOPATHOLOGYKWDbiologicalmarkersKWDhivinfections/physiopathology
970730
M9772169

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .